The global viral vector manufacturing market is expected to reach US$ 1.29 billion in 2030 from US$ 5.00 billion in 2022. The market is estimated to grow with a CAGR of 18.4% from 2022 to 2030.

Key factors driving the market growth are increasing clinical studies and development of viral-vector therapeutics and increasing demand for gene therapy. However, the complex viral-vector development process hinders the viral vector manufacturing market forecast and growth.

Market Drivers of the Viral Vector Manufacturing Market

The prevalence of genetic diseases is rising across the world and impacting the health of people at a severe level. The rise in genetic diseases is also fueling the demand for gene therapies for treatment. Genetic diseases show many symptoms that are uncommon and are mostly non-curable. Most genetic diseases are rare and are developed due to mutations in people's genetic makeup. According to The World Health Organization (WHO), 10 out of every 1,000 people were affected by single-gene diseases in 2021, signifying that 70 million and 80 million people worldwide live with any single type of single-gene disease. According to the Global Genes, ~7,000 known rare diseases and disorders have been identified worldwide, and more are discovered yearly.

According to the University of Sheffield research, ~300 million people are living with genetic diseases around the world. In 2022, a report by MJH Life Sciences (US) estimated that 300,000 newborns worldwide are born with sickle cell disease yearly, accounting for ?5% of the global population. Also, as per the study titled "Sickle Cell Disease," published in August 2023, 1 in 500 African Americans is affected by sickle cell disease, and ?1 in 12 African Americans carry the autosomal recessive mutation. In June 2020, as per Novartis AG (Switzerland) report, ?15,000 individuals had sickle cell disease in the UK, and 270 newborns are diagnosed with the condition every year. In Asia Pacific and the Middle East, a very large population is diagnosed with genetic diseases due to consanguineous marriage favored in many communities. Marriages between relatives are the major concern for the rising prevalence of genetic diseases. The burden of autosomal recessive disease variations is high in Saudi Arabia due to the highly consanguineous population. To control these conditions, countries in the Middle East are mandatorily conducting genetic evaluations for couples getting married so that the prevalence of these diseases can be managed and treated. Thus, the rising prevalence of genetic diseases fuels the demand for gene therapies, which drives viral vector manufacturing market growth.

Restraint of the Viral Vector Manufacturing Market

Developing viral vectors is a complex process involving challenges in viral vector production and quality control measures. The production of viral vectors requires specialized equipment and facilities with adherence to good manufacturing practices (GMP) practices and other regulatory standards to ensure the final product's purity, safety, and efficacy. This can pose significant challenges for manufacturers, especially smaller companies or new entrants, owing to limited resources and expertise to meet these requirements. Furthermore, large-scale viral-vector manufacturing faces various other challenges, such as the incompatibility of production systems, which may impact different stages of viral vector development. According to Patheon (service brand of Thermo Fisher Scientific), commercialization of viral vectors requires regulatory considerations to mitigate unnecessary risks such as compressed timelines, assay challenges and variability, raw materials using tumorigenic cell lines, and limited batches available at commercial scale. Thus, the complex viral vector development process hinders the growth of the viral vector manufacturing market.

Opportunities in the Viral Vector Manufacturing Market

Emerging countries such as India, China, Argentina, Brazil, UAE, and South Africa are expected to offer significant growth opportunities for viral vector market players due to rising disposable incomes, expanding patient population, increasing R&D activities, improving healthcare infrastructure, growing disease awareness, and relatively lenient guidelines compared to developed countries. According to the World Economic Forum, as of 2022, Russia, Brazil, China, India, and South Africa collectively accounted for a third of global health spending. As per the World Bank, health spending in India and China increased by 3.01% and 5.35%, respectively, from 2018 to 2019.

Furthermore, there has been an upsurge in vaccine development in emerging markets over the past decade, resulting in the expansion of biotechnology products and increasing the demand for viral vectors. For instance, according to the National Investment Promotion and Facilitation Agency of India, India is an important center for clinical trials and contract manufacturing, and it exports vaccines to more than 150 nations. Rising domestic and international demand is driving the growth of the biotechnology industry in India. Initiatives like Make in India and Aatmanirbhar Bharat drive the vaccine production in India. India's globally competitive efficacy has resulted in a demand for its vaccines and biopharmaceuticals among global consumers. Thus, the emerging biotech industry in emerging nations will increase the demand for viral vectors, boosting the viral vector manufacturing market growth.

Viral Vector Manufacturing Market: Segmental Overview

Based on the global viral vector manufacturing market analysis, the market is segmented on the basis of type, disease indication, application, and end user. Based on type, the market is divided into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and others. The adeno-associated viral vectors segment held the largest viral vector manufacturing market share in 2022. The lentiviral vectors segment is anticipated to register the highest CAGR during 2022-2030.

By disease indication, the market is segmented into cancer, genetic disorders, infectious disease, and others. The cancer segment held the largest market share in 2022. Based on the viral vector manufacturing market forecast, the genetic disorders segment is anticipated to register the highest CAGR from 2022 to 2030.

In terms of application, the market is differentiated into therapeutics development, vaccine development, and research. In 2022, the vaccine development segment held the largest viral vector manufacturing market size, and the therapeutics development segment is anticipated to register the highest CAGR during 2022-2030.

Based on end user, the market is segmented into pharmaceutical & biotechnology companies, research institutes, and CDMOs & CROs. In 2022, the pharmaceutical & biotechnology companies segment held the largest viral vector manufacturing market share and is anticipated to register the highest CAGR during 2022-2030.

Viral Vector Manufacturing Market: Geographical Overview

Asia Pacific is estimated to register the highest CAGR during 2022-2030. Countries in the Asia Pacific, such as India and China, hold significant potential for the growth of the viral vector manufacturing market. Developing countries in the region with improving healthcare infrastructure, increasing healthcare expenditure, and a rising focus on adopting advanced medical technologies offer opportunities for market expansion.

In 2022, North America held the largest global market size. The developments in medical infrastructure, the prevalence of cancer and genetic disorders, and the increasing expenditure on healthcare services across the US are the key viral vector manufacturing market trends, driving the growth of the market in the country. For instance, according to the American Cancer Society estimates, in 2022, ~1.9 million new cancer cases were diagnosed and more than 609,000 cancer deaths were reported in the US. Thus, the use of viral vectors in clinical trials, vaccine development, and biomedical research for cancer treatment and other diseases will substantially impact the viral vector manufacturing market growth.

A few of the major primary and secondary sources referred to while preparing the viral vector manufacturing market report on the viral vector manufacturing market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).